Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Intellia Soars On Positive Results In Gene-Editing Treatment  

Published 06/28/2021, 09:29 AM
Updated 06/28/2021, 09:34 AM
© Reuters.

By Dhirendra Tripathi

Investing.com – Intellia Therapeutics (NASDAQ:NTLA) rose more than 60% Monday after a phase-I study of a gene-editing treatment for a disease called transthyretin amyloidosis showed positive results.

Shares of Regeneron (NASDAQ:REGN) Pharmaceuticals, Intellia's partner in the study, gained 3%. Two other companies working on the same gene-editing technology also rallied in premarket trading, with CRISPR Therapeutics soaring 8% and Editas Medicine (NASDAQ:EDIT) rising 16%.

The stock soared because of the wider implications the gene-editing treatment holds and not just for the patients suffering from transthyretin amyloidosis.

The Intellia data showed deep reduction in the disease-causing protein after single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin amyloidosis.

NTLA-2001 is the first investigational CRISPR therapy candidate to be administered systemically, or through a vein, to edit genes inside the human body. CRISPR is a Nobel Prize-winning gene-editing technology.

Transthyretin amyloidosis, or ATTR amyloidosis, is a rare, progressive and fatal disease that occurs when a person is born with mutations in the TTR gene.

The mutation causes the liver to produce damaged proteins that then build up to cause serious complications in multiple tissues, including the heart, nerves and digestive system.

There are an estimated 50,000 people worldwide living with ATTRv amyloidosis (hereditary ATTR) and between 200,000 and 500,000 people with ATTRwt amyloidosis (wild-type ATTR).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.